Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

Table 8 Logistic regression analysis to identify patients harboring the T790M substitution through liquid biopsy (n = 58)

Variables	Univariate Analyses			Multivariate Analysis
Variables	OR	95%CI	P-value	OR	95%CI	P-value
Original mutation; absent vs. present	42.2	4.77–373.6	0.001	NI
Bone metastases; absent vs. present	48.8	5.45–436.4	0.001	77.9	5.32–1140	0.001
Enlargement of Tumor size; < 12 mm vs 12 mm ≤	0.10	0.02–0.43	0.002	NI
Brain metastases; absent vs. present	7.39	1.77–30.8	0.006	NI
Detection of New tumor lesion; < 4 vs 4 ≤	7.39	1.77–30.8	0.006	14.5	1.38–151.2	0.026
Detection of New metastatic organ; 0 → 4	1.98	1.09–3.59	0.024	NI
New minor site metastases; absent vs. present	8.44	1.21–58.8	0.031	NI
Hepatic metastases; absent vs. present	5.50	0.94–32.2	0.059	NI
Minor site metastases; absent vs. present	5.50	0.94–32.2	0.059	NI
Mutation site at initial diagnosis; Exon19 Deletion vs. L858R	3.91	0.87–17.5	0.075	1.15	0.13–10.1	0.897
New hepatic metastases; absent vs. present	5.00	0.62–40.3	0.131	NI

Abbreviations: OR Odds ratio; CI confidence interval; Variables with a p-value < 0.15 on univariate analysis were entered into multivariate logistical analysis by a simultaneous method. NI not included in the best multivariate logistic regression model

ISSN: 1471-2407